Risk factors for osteonecrosis in HIV-infected patients: Impact of treatment with combination antiretroviral therapy

AIDS

Volumn 20, Issue 12, 2006, Pages 1627-1635

  Mary Krause, Murielle ^a   Billaud, Eric ^f   Poizot Martin, Isabelle ^g   Simon, Anne ^b   Dhiver, Catherine ^h   Dupont, Caroline ^e   Salmon, Dominique ^c   Roudiere, Laurent ^d   Costagliola, Dominique ^a  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Hospital Cochin ^*  (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g HÔPITAL SAINTE MARGUERITE   (France)

^h HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Cart; Combination antiretroviral therapy; HIV infection; Osteonecrosis; Risk factors

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BONE NECROSIS; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DATA BASE; DISEASE DURATION; EXPOSURE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; TIME SERIES ANALYSIS;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MODELS, STATISTICAL; OSTEONECROSIS; RISK FACTORS; TIME FACTORS;

EID: 33746678646     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000238409.90571.02     Document Type: Article

References (43)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355:1158-9.
3. Goorney BP, Lacey H, Thurairajasingam S, Brown JDK. Avascular necrosis of the hip in a man with HIV infection. Genitourin Med 1990; 66:451-452.
4. Gerster JC, Camus JP, Chave JP, Koeger AC, Rappoport G. Multiple site avascular necrosis in HIV infected patients. J Rheumatol 1991; 18:300-302.
5. Sighinolfi L, Carradori S, Ghinelli F. Avascular necrosis of the femoral head: a side effect of highly active antiretroviral therapy (HAART) in HIV patients? Infection 2000; 28:254-255.
6. Meyer D, Behrens G, Schmidt RE, Stoll M. Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors. AIDS 1999; 13:1147-1148.
7. Monier P, McKown K, Bronze MS. Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus. Clin Infect Dis 2000; 31:1488-1492.
8. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitor. AIDS 1998; 12:F51-F58.
9. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
10. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13:2493-2505.
11. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-1052.
12. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993; 76:559-565.
13. Organisation Mondiale de la Santé. Manuel de la Classification Statistique Internationale des Maladies, Traumatismes et Causes de Décès, révision 1975. Geneva: Organisation Mondiale de la Santé; 1977.
14. Organisation Mondiale de la Santé. Classification Statistique Internationale des Maladies et des Problèmes de Santé Connexes, 10th révision. Geneva: Organisation Mondiale de la Santé; 1993.
15. Munoz A, Sabin CA, Phillips AN. The incubation period of AIDS. AIDS 1997; 11 (Suppl A):S69-S76.
16. Ancelle-Park RA. Expanded European AIDS definition. Lancet 1993; 341:441.
17. Lanoy E, Mary-Krause M, Tattevin P, Perbost I, Poizot-Martin I, Dupont C, et al. How does delayed access to care influence the survival of HIV patients during the HAART era? 15th International Conference on AIDS. Bangkok, July 2004 [abstract ThPeB7138].
18. Miller KD, Masur H, Jones EC, Joe GO, Rick ME, Kelly GG, et al. High prevalence of osteonecrosis on the femoral head in HIV-infected adults. Ann Intern Med 2002; 137:17-24.
19. DeSmet AA, Dalinka MK, Alazraki N, Berquist TH, Daffner RH, el-Khoury GY, et al. Daignostic imaging of avascular necrosis of the hip. American College of Radiology appropriateness criteria. Radiology 2000; 215 (Suppl):247-254.
20. Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ. Radionuclide bone imaging: an illustrative review. Radiographics 2003; 23:341-358.
21. Assouline-Davan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002; 32:94-124.
22. Scribner AN, Troia-Cancio PV, Cox BA, Marcantonio D, Hamid F, Keiser P, et al. Osteonecrosis in HIV: a case-control study. J Acquir Immune Defic Syndr 2000; 25:19-25.
23. Oinumaz K, Harada Y, Nawata K, Takabayashi K, Abe I, Kamikawa K, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 2001; 60:1145-1148.
24. Glesby MJ, Hoover DR, Vaamonde CM. Osteonecrosis in patients infected with human immunodeficiency virus: a case-control study. J Infect Dis 2001; 184:519-523.
25. Cheonis N. Osteonecrosis and HIV disease. Bull Exp Treat AIDS 2002; 15:22-29.
26. Allison G, Bostrom M, Glesby M. Osteonecrosis in HIV disease: epidemiology, etiologies, and clinical management. AIDS 2003; 17:1-9.
27. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005; 118 (Suppl 2):23S-28S.
28. El-Sadr W, Reiss P, De Wit S, D'Arminio Monforte A, Thiébaut R, Morfeldt L, et al. Relationship between prolonged exposure to combination ART and myocardial infarction: effect of sex, age, and lipid changes. Twelfth Conference on Retroviruses and Opportunistic Infections. Boston, February 2005 [abstract 42].
29. Calza L, Manfredi R, Mastroianni A, Chiodo F. Osteonecrosis and highly active antiretroviral therapy during HIV infection: report of a series and literature review. AIDS Patient Care STD 2001; 15:385-389.
30. Blacksin MF, Kloser PC, Simon J. Avascular necrosis of bone in human immunodeficiency virus infected patients. Clin Imaging 2000; 23:314-318.
31. Fessel W, Hurley LB. Is HIV sequestered in bone? Possible. AIDS 2003; 17:255-257.
32. Rademaker J, Dobro JS, Solomon G. Osteonecrosis and human immunodeficiency virus infection. J Rheumatol 1997; 24:601-604.
33. Newman MD. Bone disorders, hypertension, and mitochondrial toxicity in HIV disease. Top HIV med 2003; 11:10-15.
34. Savès M, Chêne G, Ducimetière P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292-298.
35. Miller KD, Masur H, Jones EC, Joe GO, Magaret E, Kelly GG, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137:E17-E25.
36. Gutiérrez F, Padilla S, Ortega E, Garcia JA, Flores J, Galera C, et al. Avascular necrosis of the bone in HIV-infected patients: incidence and associated factors. AIDS 2002; 16:481-495.
37. Hasse B, Ledergerber B, Egger M, Flepp M, Bachmann S, Bernasconi E, et al. Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV cohort study: a nested case-control study. AIDS Res Hum Retroviruses 2004; 20:909-915.
38. Lawson-Ayayi S, Bonnet F, Bernardin E, Ragnaud JM, Lacoste D, Malvy E. Avascular necrosis in HIV-infected patients: a case-control study from the Aquitaine Cohort, 1997-2000, France. Clin Infect Dis 2005; 40:1188-9311.
39. Roudière L, Viard JP. Osteonecrosis of the hip, lipodystrophy and antiretroviral treatment. AIDS 2000; 14:2056.
40. Weiel JE, Lenhard JM. Bone mineral loss in HIV-positive patients receiving antiretroviral therapy. AIDS 2000; 14:2218-2219.
41. Collins ML, Sondel N, Cesar D, Hellerstein MK. Effect of nucleoside reverse transcriptase inhibitors on mitochondrial DNA synthesis in rats and humans. J Acquir Immune Defic Syndr 2004; 37:1132-1139.
42. Nolan D, Hammond E, James I, McKinnon E, Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8:617-626.
43. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001; 33:1931-1937.